Obesity evidence dossier

Ribupatide

A late-stage injectable GLP-1/GIP program with strong company-reported Phase 2 weight-loss data; confirmatory global Phase 3 efficacy is pending.

Kailera Therapeutics, Inc. (licensed from Hengrui Pharma outside Greater China)Global Phase 3 (KaiNETIC obesity program)Subcutaneous injection, once weekly

Weight loss score /10074

Comparison statusOther trial data · Includes treatment stops

EvidencePhase 3 · Sponsor disclosure

Follow-up48 weeks

Total weight loss

17.7%

GEMINI-1 · 6 mg weekly · week 48 · Includes treatment stops

Placebo-adjusted

16.3%

Difference from placebo in the same study when reported.

Study context

Once-weekly injectable GLP-1/GIP receptor dual-agonist peptide./Adults with obesity or overweight in China, without diabetes/567 participants across the study/48-week endpoint

Baseline: See the source for enrollment criteria

Ranked result & calculation

GEMINI-1 · 6 mg weekly · 48 weeks

Adults with obesity or overweight in China, without diabetes. 567 participants across the study (not this dose arm alone).

Includes treatment stops. Treatment-policy results estimate outcomes regardless of stopping treatment.

Average weight loss: 17.7%
Placebo group: 1.4% loss
Beyond placebo: 16.3 percentage points (arm subtraction)
Stopped due to adverse events: Not verified for this result

Selected Phase 3 treatment-policy result at 6 mg. The separate 8 mg Phase 2 result is not mixed into this score.

Score: 70% × 72.8 total-loss points + 30% × 76.7 beyond-placebo points = 74/100, rounded. Conversion scales

Alternative analysis assuming continued treatment: 19.2% total loss. This is not the result used for the headline score. Alternative analysis source ↗

Hengrui / Kailera, GEMINI-1 ↗Phase 3 · Sponsor disclosure · Reviewed 2026-09-21

Evidence

Benchmark read

GEMINI-1: Includes treatment stops. Selected Phase 3 treatment-policy result at 6 mg. The separate 8 mg Phase 2 result is not mixed into this score.

Safety

Side effects and cautions

Discontinuation read

Adverse-event discontinuation has not been verified for this result.

Common side effects

Kailera describes injectable safety and tolerability as consistent with the approved GLP-1-based class.

Main cautions

Investigational and not approved; long-term comparative safety and efficacy require Phase 3 confirmation.

Upcoming catalyst

What to watch next

KaiNETIC Phase 3 readouts; Phase 2b high-dose injectable study data anticipated in 2027.

Linked clinical trials

Trials in the saddl3 obesity snapshot

Non-diabetic obesity studies are prioritized; diabetes and healthy-volunteer studies remain visible and labeled.

NCT07285902

Phase 3

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

Fujian Shengdi Pharmaceutical Co., Ltd.

Non-diabetic obesity

Active

Feb 27, 2026

NCT06994650

Phase 3

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy

Fujian Shengdi Pharmaceutical Co., Ltd.

Non-diabetic obesity

Recruiting

Jan 26, 2026

NCT06974851

Phase 3

A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity

Fujian Shengdi Pharmaceutical Co., Ltd.

Non-diabetic obesity

Recruiting

Nov 17, 2025

NCT06396429

Phase 3

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

Fujian Shengdi Pharmaceutical Co., Ltd.

Non-diabetic obesity

Completed

Jul 11, 2025

NCT07150962

Phase 1

Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects

Fujian Shengdi Pharmaceutical Co., Ltd.

Non-diabetic obesity

Recruiting

Nov 17, 2025

NCT07284901

Phase 3

Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Kailera

Type 2 diabetes / obesity

Recruiting

Mar 31, 2026

NCT07284979

Phase 3

Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Kailera

Type 2 diabetes / obesity

Recruiting

Mar 13, 2026

NCT07284875

Phase 3

Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Kailera

Type 2 diabetes / obesity

Recruiting

Mar 2, 2026

NCT07458269